A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  • STATUS
    Not Recruiting
  • End date
    Apr 6, 2027
  • participants needed
    8250
  • sponsor
    AbbVie
Updated on 26 January 2021
Investigator
AbbVie_Call Center
Primary Contact
Universitaetsklinikum Erlangen /ID# 128179 (8.7 mi away) Contact
+568 other location

Summary

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

Details
Condition Ulcerative Colitis, Ulcerative Colitis (Pediatric)
Clinical Study IdentifierNCT01848561
SponsorAbbVie
Last Modified on26 January 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note